Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immunoprecipitation01:20

Immunoprecipitation

Immunoprecipitation, or IP, is a widely used technique that employs protein-antibody interactions to isolate proteins or protein complexes in their native state for studying protein-protein interactions, quaternary structures, or supramolecular complexes. Various modifications of the technique, including chromatin IP, cross-linking IP, and fluorescence IP, are commonly used.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
Immunological Memory01:23

Immunological Memory

Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature is...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synagis: an anti-RSV monoclonal antibody.

Pediatric nursing·2002
Same author

Evaluation of outcomes in converting from intravenous ondansetron to oral granisetron: an observational study.

The Annals of pharmacotherapy·2001
Same author

Anagrelide, a selective thrombocytopenic agent.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1998
Same author

Ciprofloxacin-induced toxic epidermal necrolysis.

The Annals of pharmacotherapy·1996

Related Experiment Video

Updated: May 22, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

RespiGam: an RSV immune globulin

M D Oertel1

  • 1University of North Carolina Hospitals, Department of Pharmacy, in Chapel Hill, USA.

Pediatric Nursing
|November 1, 1996
PubMed
Summary

Respiratory syncytial virus immune globulin (RSV-IG) effectively prevents lower respiratory tract infections in high-risk infants. However, its high cost necessitates careful consideration for eligible candidates.

Area of Science:

  • Pediatrics
  • Immunology
  • Infectious Diseases

Background:

  • Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants.
  • Infants with bronchopulmonary dysplasia (BPD) or born prematurely (<35 weeks gestation) are at higher risk for severe RSV disease.
  • RSV immune globulin (RSV-IG) prophylaxis is available to reduce RSV-related morbidity in these vulnerable infants.

Purpose of the Study:

  • To evaluate the efficacy of RSV-IG in preventing or attenuating RSV lower respiratory tract infections.
  • To discuss the cost-effectiveness and appropriate use of RSV-IG in eligible infant populations.

Main Methods:

  • Review of existing clinical data on RSV-IG efficacy in infants with BPD or prematurity.
  • Analysis of the economic implications of seasonal RSV-IG prophylaxis.

More Related Videos

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

Related Experiment Videos

Last Updated: May 22, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

Main Results:

  • RSV-IG has demonstrated effectiveness in preventing or reducing the severity of RSV lower respiratory tract infections in infants under 24 months with BPD or born prematurely.
  • The estimated cost for seasonal prophylaxis ranges from $4,000 to $5,000 per infant.

Conclusions:

  • RSV-IG is a valuable tool for protecting high-risk infants from severe RSV disease.
  • The significant cost of RSV-IG, coupled with the potential risks associated with blood products, warrants careful patient selection for prophylaxis.